Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Summary

This phase II trial is studying erlotinib to see how well it works in treating patients with persistent or recurrent cancer of the cervix. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor

Timeline

Start

2002-03

Primary completion

2005-11

Completion

—

Drugs

Indications